We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
2.00 | 0.02% | 11,252.00 | 11,250.00 | 11,252.00 | 11,362.00 | 11,222.00 | 11,250.00 | 2,107,121 | 16:03:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 29.27 | 174.3B |
TIDMAZN
RNS Number : 6730N
AstraZeneca PLC
10 August 2017
10 August 2017 13:30 BST
Publication of Prospectus
Following a routine technical update of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the UK Listing Authority and is available for viewing:
Base Prospectus for the AstraZeneca PLC U.S. $5,000,000,000 Euro Medium Term Note Programme (the "Prospectus").
The last drawdown under the EMTN programme was in 2016.
To view the full document, please paste the following URL into the address bar of your browser.
http://www.rns-pdf.londonstockexchange.com/rns/6730N_-2017-8-10.pdf
A copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:
http://www.morningstar.co.uk/uk/NSM
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
Media Relations Esra Erkal-Paler UK/Global +44 203 749 5638 Rob Skelding UK/Global +44 203 749 5821 Karen Birmingham UK/Global +44 203 749 5634 Matt Kent UK/Global +44 203 749 5906 Jacob Lund Sweden +46 8 553 260 20 Michele Meixell US +1 302 885 2677 Investor Relations Thomas Kudsk Larsen +44 203 749 5712 Craig Marks Finance, Fixed Income, M&A +44 7881 615 764 Henry Wheeler Oncology +44 203 749 5797 Mitchell Chan Oncology +1 240 477 3771 Christer Gruvris Diabetes; Autoimmunity, Neuroscience & Infection +44 203 749 5711 Nick Stone Respiratory; Brilinta +44 203 749 5716 US toll free +1 866 381 7277
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS
The company news service from the London Stock Exchange
END
PDIOKKDNDBKDOFD
(END) Dow Jones Newswires
August 10, 2017 08:30 ET (12:30 GMT)
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions